Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01228058 · ClinicalTrials.gov registry record
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
A clinical trial, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- 1,450
- Enrollment target
NCT01228058 is a clinical trial that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 1,450 participants.
The verdict
NCT01228058 has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- 1,450 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical utility of thrombelastography (TEG) to predict and identify trauma patients at increased risk of receiving blood transfusion, develop multiple organ failure and mortality. TEG has been proposed as a superior tool to rapidly diagnose and help guide resuscitation with blood products and preclinical data suggest that TEG is both more sensitive and specific than PT or PTT for coagulation abnormalities. Based on the preclinical work led by Dr. Holcomb, our hypothesis is that the Rapid TEG will help to identify these coagulopathic patients earlier, allow for rapid MT protocol activation, and assist in developing data driven blood product transfusion guidelines.
Interventions
- PROCEDURE RapidTEG test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,450 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01228058
The ClinicalTrials.gov registry entry for NCT01228058 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RapidTEG test is the first listed.
NCT01228058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01228058 about?
NCT01228058 is a clinical study titled "A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients". The purpose of this study is to evaluate the clinical utility of thrombelastography (TEG) to predict and identify trauma patients at increased risk of receiving blood transfusion, develop multiple organ failure and mortality. TEG has been proposed as a superior tool to rapidly diagnose and help gui...
What is the current status of trial NCT01228058?
This trial is currently completed. The enrollment target is 1,450 participants. The study started on 2010-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01228058?
The interventions under investigation include: RapidTEG test (PROCEDURE).
Who is sponsoring clinical trial NCT01228058?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.